New Legal Resource Launches for GLP-1 Users Experiencing Vision Loss

DALLAS - March 13, 2026 - PRLog -- Following the formation of MDL 3163 for GLP-1 receptor agonist vision loss claims, a new educational resource has launched to help affected patients understand their rights and the emerging litigation.

GLP1VisionLawsuit.com provides free information about the connection between GLP-1 medications including Ozempic, Wegovy, and Mounjaro and non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden, permanent vision loss.

A July 2024 study published in JAMA Ophthalmology by researchers at Harvard's Massachusetts Eye and Ear found that patients using semaglutide (the active ingredient in Ozempic and Wegovy) faced significantly elevated risk of developing NAION compared to non-users. The findings prompted federal judicial coordination of related lawsuits into a single MDL in the Southern District of Florida.

The litigation alleges that Novo Nordisk and Eli Lilly failed to adequately warn patients and prescribers about the NAION risk associated with their GLP-1 medications, despite mounting evidence from FDA adverse event reports and clinical research.

Millions of Americans are taking GLP-1 medications for diabetes and weight loss. Those experiencing vision changes deserve clear information about the potential connection and their legal options.

Resources Available:
Free eligibility screening - https://glp1visionlawsuit.com/do-i-qualify/
Understanding NAION risk - https://glp1visionlawsuit.com/what-is-naion/
State filing deadlines - https://glp1visionlawsuit.com/states/
FAQ - https://glp1visionlawsuit.com/faq/

About Ruja Media
Ruja Media provides legal information resources connecting individuals affected by pharmaceutical and environmental litigation with qualified legal representation. The organization is not a law firm.

Media Contact:
Editorial Team
info@glp1visionlawsuit.com
https://glp1visionlawsuit.com